Russia Offers Incentives To Welcome Import Of China's Pharmaceutical Products
This article was originally published in PharmAsia News
Russia and China have jointly pushed for the registration of China's drugs in Russia
You may also be interested in...
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Manufacturers warned to keep better electronic records and not falsify data in recent warning letters, ICH adds three residual solvent limits for pharmaceuticals, and the Polish authority hits firm for GMP noncompliance.
Washington State Sen. Patty Murray said at a 4 June health panel hearing that having USPHS Admiral Brett Giroir step down as the nation’s COVID-19 “Testing Czar” is a bad move, but HHS disagrees.